MedWatch

CEO of the Lundbeck Foundation defends share split proposal

The Lundbeck Foundation’s proposed new share structure, which comes with differentiated voting rights, should not be viewed as a grasp for power. Rather, the move is meant to provide stability, says CEO Lene Skole.

Lene Skole, CEO at the Lundbeck Foundation | Photo: Gregers Tycho/ERH

It provoked criticism when the majority stakeholder in pharmaceutical firm Lundbeck, the Lundbeck Foundation, proposed a new share structure entailing shares with weaker voting rights than others. Opponents said this would dilute shares without the majority owner having to relinquish any power.

In an interview with Danish media Finans, CEO at the Lundbeck Foundation Lene Skole rejects this notion:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs